Wim Goettsch has accepted a position as special HTA-advisor at the Dutch National Healthcare Institute. In this new role he is responsible for the alignment of European Health Technology Assessment methods with the processes of Zorginstituut Nederland. Dr. Goettsch will discontinue his position as Director of the European Network for Health Technology Assessment (EUnetHTA) and assume his new role as of March 15, 2018.
Wim Goettsch has played an important role during the first stages of EUnetHTA JA3 including its growth from 36 to 81 collaborating partner institutions.
At the Dutch National Health Care Institute Goettsch will act as special advisor to the Board on EUnetHTA (related) matters. Also, he will advise EUnetHTA from the perspective of the Dutch National Health Care Institute regarding EUnetHTA Work Package 4 on joint relative effectiveness assessments of pharmaceuticals.
Wim Goettsch will combine his advisory role with a position as Associate Affiliate Professor of International Collaboration in HTA at Utrecht University.
Ensuring continued progress
Wim Goettsch was appointed as Director of EUnetHTA Joint Action 3 (JA3) in June 2016. He is an internationally recognized expert on scientific research for HTA and implementation through collaboration within the EU and globally. Under his directorship EUnetHTA introduced new models for ‘Early Dialogues’ and Joint Assessments that are applicable throughout the EU.
The vacant position of Director EUnetHTA JA3 will not be re-appointed. In consultation with EUnetHTA’s Executive Board changes to the governance of EUnetHTA will be implemented to ensure continued progress during this important phase of EU collaboration on HTA.